5 Health-Care Stocks Getting Slaughtered

In this edition, health-care editor and analyst David Williamson takes a closer look at the five biggest losers in the sector for the week. Watch and find out which stocks plunged and, more importantly for investors, why the market punished them. Fool on!

One way to shield yourselves from the whims of the market is to invest in strong dividend-paying stocks. The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called  "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.

Dave Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Health Management Associates. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (4) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 29, 2012, at 3:21 PM, genesis667 wrote:

    Nice try, but they would not hurt Belviq sales since the generics are already available right now and have been for years....The analyst community refuses to face reality that they will indeed hurt Qsymia sales...

  • Report this Comment On July 29, 2012, at 5:28 PM, Foreeverlong wrote:

    "A generic version of Qsymia would hurt Belviq's sales".

    Dave,

    I don't agree. Genesis indicated above, both component drugs (Phentermine and Topiramate) have been available in generic form for years. Dr.'s simply don't order them for weight reduction to any great degree.

    Qsymia will fail because it is dangerous to prescribe, and as a result Qsymia has a very burdensome FDA REMS that the vast majority of Dr.'s are not going to want to deal with.

    Belviq can easily be combined to Phentermine for a safe and even more efficacious weight reduction solution. So, physicians will find no need for Qsymia.

    My compliments on the fact that you are one of the few people that I have heard reference how bizarre it is that the management of Vivus has not responded to the Citron report. But, again the Citron report is only tip of the iceberg when it comes to Vivus'es problems.

    Management knew when to sell their shares.

  • Report this Comment On July 31, 2012, at 12:43 AM, Rdmize wrote:

    Bad reporting and bad information.

  • Report this Comment On July 31, 2012, at 11:10 AM, WCoastGuynCA wrote:

    Mannkind, MNKD, at $2.50/share is one of the best opportunities to make substantial profits over the next twelve months as its diabetes drug, Afrezza, moves towards F.D.A. approval. Especially with the possibility of a "big pharma" marketing partnership lurking in the background.

Add your comment.

DocumentId: 1962919, ~/Articles/ArticleHandler.aspx, 7/28/2014 12:20:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement